Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PPM1B | O75688 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26663150 | 0.90 | ALDH1A1 (0.45) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL103276 | 0.89 | MAPT (0.51) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL34476509 | 0.88 | ALDH1A1 (0.48) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL422879 | 0.85 | MAPT (0.46) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL34475471 | 0.83 | ALDH1A1 (0.49) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2432868 | 0.80 | MAPT (0.47) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2432863 | 0.80 | MAPT (0.47) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2432866 | 0.80 | MAPT (0.47) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13104069 | 0.79 | TP53 (0.38) | — | |
| SCHEMBL16048822 | 0.79 | TP53 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634159-A1 | SULFOXIMINES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025034858-A1 | FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20240252473-A1 | Sulfoximines as inhibitors of NaV1.8 | GRUENENTHAL GMBH (DE) | 2024-08-01 | — | — | US | disclosed |
| WO-2024126648-A1 | SULFOXIMINES AS INHIBITORS OF NaV1.8 | Grünenthal GmbH (DE) | 2024-06-20 | — | — | WO | disclosed |
| EP-4385984-A1 | PYRIDINE-N-OXIDES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2024-06-19 | — | — | EP | disclosed |
| US-11999699-B2 | Substituted pyrazole amides | Grünenthal GmbH (DE) | 2024-06-04 | — | — | US | disclosed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| CN-111018861-B | Pyrrolopyrimidine compounds | 正大天晴药业集团股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3235819-B1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL AS JAK INHIBITORS | CENTAURUS BIOPHARMA CO LTD (CN) | 2020-11-18 | — | — | EP | disclosed |
| US-7732440-B2 | Phenothiazin derivatives, method for the production thereof and use thereof as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-06-08 | — | — | US | disclosed |
| US-7732440-B2 | Phenothiazin derivatives, method for the production thereof and use thereof as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-06-08 | — | — | US | disclosed |
| US-7732440-B2 | Phenothiazin derivatives, method for the production thereof and use thereof as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-06-08 | — | — | US | disclosed |
| US-20090325942-A1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-31 | — | — | US | disclosed |
| US-20090325942-A1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-31 | — | — | US | disclosed |
| US-20090325942-A1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-31 | — | — | US | disclosed |
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2008089892-A1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-07-31 | — | — | WO | disclosed |
| EP-1805196-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | AstraZeneca AB (SE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006040558-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999699-B2 | Substituted pyrazole amides | SCN8A, SCN1A, SCN7A | MAPT 2901/4885CYP3A4 551/4885CYP2D6 324/4885 |
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | MAPT 4388/4885CYP3A4 889/4885CYP2D6 301/4885 |
| US-20090325942-A1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | CYP2D6, CYP1B1, CYP4B1 | MAPT 772/4885CYP3A4 7/4885CYP2D6 1/4885 |
| US-20240252473-A1 | Sulfoximines as inhibitors of NaV1.8 | SCN8A, SCN10A, SCN7A | MAPT 4439/4885CYP3A4 2359/4885CYP2D6 913/4885 |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | SCN8A, SCN1A, SCN7A | MAPT 2901/4885CYP3A4 551/4885CYP2D6 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.